Researchers at the Icahn School of Medicine at Mount Sinai have uncovered genetic links between inflammatory bowel disease and Parkinson’s disease, suggesting potential for shared therapeutic strategies. The study identified mutations in the LRRK2 gene as a common element and highlighted novel genes likely affecting individuals with both conditions. The research team used advanced genomic analysis on data from the Mount Sinai BioMe BioBank, the UK Biobank, and the Danish National Biobank, examining rare genetic variants and discovering new biological pathways involving immunity, inflammation, and autophagy.
The research not only identifies genetic connections but also opens the door for innovative treatments and prevention strategies. By pinpointing common genetic underpinnings, the study paves the way for novel drug targets and the repurposing of existing drugs, potentially transforming treatment approaches. This work, funded by the Michael J. Fox Foundation, NIH, and the Charles Bronfman Institute, underscores the importance of genetic research in developing personalized medicine.
Reference: Mount Sinai Study Identifies Genetic Link Between Inflammatory Bowel Disease and Parkinson’s Disease. Mount Sinai Health System. Published May 13, 2024. Accessed June 23, 2024. https://www.mountsinai.org/about/newsroom/2024/mount-sinai-study-identifies-genetic-link-between-inflammatory-bowel-disease-and-parkinsons-disease
